FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study - Arcellx (NASDAQ:ACLX)

The move follows alignment with FDA on modifications to the iMMagine-1 trial protocol related to preventing and managing the risk of adverse events within the trial.

The company anticipates presenting preliminary data from the iMMagine-1 study in the second half of 2024.

The FDA issued the clinical hold after a patient's death who was treated with CART-ddBCMA despite becoming ineligible for treatment under the trial protocol before CART-ddBCMA infusion.

Subsequently, the patient was managed in a manner that conflicted with the trial protocol.

Arcellx had cash, cash equivalents, and marketable securities of $506.5 million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026.

Price Action: ACLX shares are down 0.09% at $33.66 premarket on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ:ACLX) iMMagine-1 Phase 2 Clinical Program.

The move follows alignment with FDA on modifications to the iMMagine-1 trial protocol related to preventing and managing the risk of adverse events within the trial.

As a key effort to enhance protocol adherence, Arcellx retrained clinical sites. Additionally, FDA allowed an expansion of treatment options for therapies that patients in the iMMagine-1 trial can receive between apheresis and CAR-T infusion (also known as bridging therapies) to align its protocol with current clinical practice better.